Evidence map›Paper›PMID 37361206›Full record

ArticleFrontiers in pharmacology2023

Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach.

Marco Mele, Paola Imbrici, Antonietta Mele, Maria Vittoria Togo, Giorgia Dinoi, Michele Correale, Natale Daniele Brunetti, Orazio Nicolotti, Annamaria De Luca, Cosimo Damiano Altomare and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marco MeleDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Paola ImbriciDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Antonietta MeleDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Maria Vittoria TogoDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Giorgia DinoiDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Michele CorrealeUniversity Hospital Policlinico Riuniti, Foggia, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Orazio NicolottiDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Annamaria De LucaDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Cosimo Damiano AltomareDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Antonella LiantonioDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Nicola AmorosoDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
University of Bari Aldo Moro · ITOspedali Riuniti di Foggia · ITUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

explainable artificial intelligencegliflozinsheart failuremachine learningsodium-glucose cotransporter 2 inhibitor

Identifiers

PMID37361206
PMCPMC10289166
OpenAlexW4380078239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.